Status:
RECRUITING
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Lead Sponsor:
University of Alberta
Conditions:
Immunosuppression
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunctio...
Detailed Description
Excellent short-term survival following liver transplantation (LT) has translated into long-term survival with many patients surviving over 25 years (1). Thus, many patients will have prolonged exposu...
Eligibility Criteria
Inclusion
- 2 years or more post-liver transplant
- 18 years or older
Exclusion
- diagnosis of either acute or chronic rejection in the past 12 months
- abnormal liver enzymes (ALT \> 50; bilirubin \> 19 umol/L)
- transplant for autoimmune liver disease (autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis)
- presence of HCV RNA
- presence of HBV DNA
- presence of class II donor specific antibodies (DSA; pre-existing or de novo)
- beyond 6 years of transplantation
- presence of ascites, decompensated heart failure, biliary obstruction, CKD (bl eGFR 30 ml/min/1.73m2 or less), re-transplantation, or multi-visceral transplant.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07206277
Start Date
December 1 2025
End Date
December 31 2028
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G2R3